Sanofi, Regeneron burnish their blockbuster Dupixent franchise with positive results in children with uncontrolled eczema

As a stable of new players sets out to topple Dupixent’s status as the reigning antibody treatment for atopic dermatitis, the blockbuster’s developers are moving the goalposts.

Dupixent has aced a Phase III trial involving 162 children between 6 months and 5 years old, Sanofi and Regeneron say, becoming the...

Click to view original post